Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4280A vs Standard of Care in Previously Treated Metastatic Colorectal Cancer
NCT05064059Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of favezelimab, pembrolizumab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Nov 2021; status: completed.
02
Drugs
favezelimabpembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05064059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064059.